Product Details
| Product Name:
INF39 |
CAS No.:
866028-26-4 |
| Purity:
99.78% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | INF39 |
| Description | INF39 is a noncytotoxic and irreversible NLRP3 inhibitor. |
| Cell Research | Human THP-1 cells were exposed to INF39 (0.1?100 μM, 72 h), and then cell viability was evaluated by the MTT assay. |
| Animal Research | Animal Models: Male Sprague?Dawley rats. Solvent: olive oil. Dosages: 12.5,25.0,50.0 mg/kg/day,p.o. |
| In vitro | INF39 possibly reacts with Cys-SH residues in the active site of cysteine protease caspase-1 but does not directly inhibit caspase-1 activity. INF39 (10 μM) can markedly inhibit ATP- and nigericin-induced IL-1β release. In the macrophages, INF39 suppresses caspase-1 activation and pyroptosis. INF39 can also block the NF-κB pathway. INF39 can reduce the steady-state (or basal) BRET signal of NLRP3, and not affect the viability of cells. INF39 cannot affect the initial conformational changes suffered by NLRP3 upon sensing the decrease of intracellular K+, but it affects the second step of NLRP3 conformational change. INF39 reaches the intestinal epithelium without undergoing chemical modifications. It is likely to act locally at the mucosal epithelial level after absorption into epithelial cells. |
| In vivo | INF39 (p.o.) reduces systemic and colonic inflammation in rats treated with 2,4- dinitrobenzene sulfonic acid. In inflamed rats, INF39 (12.5/25/50 mg/ kg) markedly increases body weight. DNBS causes a significant increment of spleen weight (+39.3%). This increase is markedly reduced by administration of INF39 (+2.2, +4.3 and +4.8% at 12.5, 25, 50 mg/kg, respectively). The inhibition of NLRP3 inflammasome complex with INF39 can dose-dependently attenuate the decrease in colonic length (?19, ?13 and ?8% at 12.5, 25, 50 mg/kg, respectively). Rats treated with INF39 shows a significant reduction of macroscopic damage score (4.7 at 12.5 mg/kg, 3.1 at 25 mg/kg, and 2.8 at 50 mg/kg). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 10 mg/mL (44.51 mM)
|
| Keywords | inhibit | INF 39 | INF-39 | NOD-like Receptor (NLR) | INF39 | Inhibitor |
| Inhibitors Related | Stavudine | Dapansutrile | NOD-IN-1 | MCC950 sodium | Imperatorin | Muscone | NLRP3-IN-2 | Bergenin | Troxerutin | NLRP3-IN-9 | Selnoflast | JC2-11 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Nonsteroidal Anti-Inflammatory Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Breast Cancer Compound Library | Pyroptosis Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:794494-38-5
$78.00 / 1mg
-
CAS:157134-53-7
$230.00 / 1mg
-
CAS:1210344-83-4
$39.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.00/1g |
VIP5Y
|
Career Henan Chemica Co
|
2020-11-12 |
United States